FILE 'REGISTRY' ENTERED AT 15:16:56 ON 23 JUL 2004
L40 10 S ADWSWA/SQSP

FILE 'CAPLUS' ENTERED AT 15:17:03 ON 23 JUL 2004
L41 1 S L40

L41 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2004 ACS on STN
ED Entered STN: 09 Nov 2001
ACCESSION NUMBER: 2001:816734 CAPLUS
DOCUMENT NUMBER: 135:352790
TITLE: Anti-inflammatory compounds and uses thereof
INVENTOR(S): May, Michael J.; Ghosh, Sankar; Findeis, Mark A.; Phillips, Kathryn
PATENT ASSIGNEE(S): Praecis Pharmaceuticals Incorporated, USA; Yale University
SOURCE: PCT Int. Appl., 88 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083554	A2	20011108	WO 2001-US14346	20010502
WO 2001083554	A3	20020801		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1280820	A2	20030205	EP 2001-935035	20010502
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003054999	A1	20030320	US 2001-847946	20010502
JP 2003531918	T2	20031028	JP 2001-580978	20010502

PRIORITY APPLN. INFO.:
US 2000-201261P P 20000502
US 2000-643260 A 20000822
WO 2001-US14346 W 20010502

OTHER SOURCE(S): MARPAT 135:352790

AB The present invention provides anti-inflammatory compds., pharmaceutical compns. thereof, and methods of use thereof for treating inflammatory disorders. The present invention also provides methods of identifying anti-inflammatory compds. and methods of inhibiting NF-κB-dependent target gene expression in a cell. The present invention is based , at least in part, on the identification of the NEMO (NF-κB essential modulator) binding domain (NBD) on IκB kinase-α (IKKα) and on IκB kinase-β (IKKβ). Accordingly, in one aspect, the present invention provides anti-inflammatory compds. which are

peptides comprising a NEMO binding domain. In on embodiment, the present invention provides anti-inflammatory compds. comprising fusion peptides of a NEMO binding domain and at least one membrane translocation domain. The membrane translocation domain facilitates membrane translocation of the anti-inflammatory compds.

IT **371915-71-8 371915-89-8 371915-90-1**
371915-91-2 371915-92-3 371915-93-4
371915-94-5 371915-95-6 371915-96-7
371915-97-8
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(NEMO binding sequence; fusion peptides comprising membrane translocation domain and NEMO (NF-κB essential modulator) binding domain as anti-inflammatory compds. and uses thereof)

E266 THROUGH E275 ASSIGNED

FILE 'REGISTRY' ENTERED AT 15:17:32 ON 23 JUL 2004
L42 10 SEA FILE=REGISTRY ABB=ON PLU=ON (371915-71-8/BI OR 371915-89-8/BI OR 371915-90-1/BI OR 371915-91-2/BI OR 371915-92-3/BI OR 371915-93-4/BI OR 371915-94-5/BI OR 371915-95-6/BI OR 371915-96-7/BI OR 371915-97-8/BI)

L43 10 L40 AND L42

L43 ANSWER 1 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-97-8** REGISTRY
CN L-Threonine, L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 28: PN: WO0183554 SEQID: 79 claimed protein
SQL 8

SEQ 1 ADWSWAQT
======
HITS AT: 1-6

REFERENCE 1: 135:352790

L43 ANSWER 2 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-96-7** REGISTRY
CN L-Glutamine, L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 27: PN: WO0183554 SEQID: 78 claimed protein
SQL 7

SEQ 1 ADWSWAQ
======
HITS AT: 1-6

REFERENCE 1: 135:352790

L43 ANSWER 3 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN

RN **371915-95-6** REGISTRY
CN L-Threonine, L-alanyl-L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 26: PN: WO0183554 SEQID: 77 claimed protein
SQL 9

SEQ 1 AADWSWAQT
======
HITS AT: 2-7

REFERENCE 1: 135:352790

L43 ANSWER 4 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-94-5** REGISTRY
CN L-Glutamine, L-threonyl-L-alanyl-L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 25: PN: WO0183554 SEQID: 76 claimed protein
SQL 9

SEQ 1 TAADWSWAQ
======
HITS AT: 3-8

REFERENCE 1: 135:352790

L43 ANSWER 5 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-93-4** REGISTRY
CN L-Threonine, L-threonyl-L-alanyl-L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl-L-glutaminyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 24: PN: WO0183554 SEQID: 75 claimed protein
SQL 10

SEQ 1 TAADWSWAQT
======
HITS AT: 3-8

REFERENCE 1: 135:352790

L43 ANSWER 6 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-92-3** REGISTRY
CN L-Glutamic acid, L-alanyl-L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl-L-glutaminyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 21: PN: WO0183554 SEQID: 72 claimed protein
SQL 10

SEQ 1 AADWSWAQTE
======
HITS AT: 2-7

REFERENCE 1: 135:352790

L43 ANSWER 7 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-91-2** REGISTRY
CN L-Alanine, L-threonyl-L-alanyl-L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 20: PN: WO0183554 SEQID: 71 claimed protein
SQL 8

SEQ 1 TAADWSWA
======
HITS AT: 3-8

REFERENCE 1: 135:352790

L43 ANSWER 8 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-90-1** REGISTRY
CN L-Glutamic acid, L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl-L-glutaminyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 19: PN: WO0183554 SEQID: 70 claimed protein
SQL 9

SEQ 1 ADWSWAQTE
======
HITS AT: 1-6

REFERENCE 1: 135:352790

L43 ANSWER 9 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-89-8** REGISTRY
CN L-Glutamic acid, L-threonyl-L-alanyl-L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl-L-alanyl-L-glutaminyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 18: PN: WO0183554 SEQID: 69 claimed protein
SQL 11

SEQ 1 TAADWSWAQT E
======
HITS AT: 3-8

REFERENCE 1: 135:352790

L43 ANSWER 10 OF 10 REGISTRY COPYRIGHT 2004 ACS on STN
RN **371915-71-8** REGISTRY
CN L-Alanine, L-alanyl-L-α-aspartyl-L-tryptophyl-L-seryl-L-tryptophyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 42: PN: WO0183554 SEQID: 42 claimed protein
SQL 6

SEQ 1 ADWSWA
======
HITS AT: 1-6

REFERENCE 1: 135:352790

(FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 15:17:58 ON 23 JUL 2004)
L44 0 S L40

FILE 'HOME' ENTERED AT 15:18:08 ON 23 JUL 2004

Mitra
09/847940
Seq. ID 6 out

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: July 23, 2004, 13:11:28 ; Search time 52 Seconds
(without alignments)
32.602 Million cell updates/sec

Title: US-09-847-940C-6
Perfect score: 40
Sequence: 1 ADWSWA 6

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 50 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	40	100.0	6	5	AAM48538	Aam48538 Anti-infl
2	40	100.0	6	5	AAM48570	Aam48570 Anti-infl
3	40	100.0	6	6	ADA61814	Ada61814 NFkB esse
4	40	100.0	6	6	ADA61846	Ada61846 NFkB esse
5	40	100.0	7	5	AAM48574	Aam48574 Anti-infl
6	40	100.0	7	6	ADA61850	Ada61850 NFkB esse
7	40	100.0	8	5	AAM48575	Aam48575 Anti-infl
8	40	100.0	8	5	AAM48567	Aam48567 Anti-infl
9	40	100.0	8	6	ADA61851	Ada61851 NFkB esse
10	40	100.0	8	6	ADA61843	Ada61843 NFkB esse
11	40	100.0	9	5	AAM48573	Aam48573 Anti-infl
12	40	100.0	9	5	AAM48566	Aam48566 Anti-infl
13	40	100.0	9	5	AAM48569	Aam48569 Anti-infl
14	40	100.0	9	5	AAM48572	Aam48572 Anti-infl
15	40	100.0	9	6	ADA61848	Ada61848 NFkB esse
16	40	100.0	9	6	ADA61841	Ada61841 NFkB esse
17	40	100.0	9	6	ADA61849	Ada61849 NFkB esse
18	40	100.0	9	6	ADA61845	Ada61845 NFkB esse
19	40	100.0	9	6	ADA61842	Ada61842 NFkB esse
20	40	100.0	10	5	AAM48568	Aam48568 Anti-infl
21	40	100.0	10	5	AAM48571	Aam48571 Anti-infl
22	40	100.0	10	6	ADA61844	Ada61844 NFkB esse
23	40	100.0	10	6	ADA61847	Ada61847 NFkB esse
24	40	100.0	11	5	AAM48565	Aam48565 Anti-infl
25	40	100.0	11	6	ADA61840	Ada61840 NFkB esse
26	37	92.5	33	4	AAU21305	Aau21305 Human nov
27	37	92.5	103	2	AAY06332	Aay06332 Gliocladi
28	37	92.5	236	2	AAY06363	Aay06363 Gliocladi
29	37	92.5	236	3	AAY84341	Aay84341 Amino aci
30	37	92.5	236	3	AAB14876	Aab14876 Gliocladi
31	37	92.5	236	5	AAU77584	Aau77584 G. roseum
32	37	92.5	236	5	AAU77428	Aau77428 Gliocladi
33	37	92.5	274	5	ABP65718	Abp65718 Bifidobac
34	37	92.5	597	4	ABB62635	Abb62635 Drosophil
35	37	92.5	885	4	AAU33594	Aau33594 Pseudomon
36	37	92.5	885	6	ABU15648	Abu15648 Protein e
37	36	90.0	6	5	ABB08727	Abb08727 Mutated I
38	36	90.0	6	5	ABB08728	Abb08728 Mutated I
39	36	90.0	6	5	AAM48537	Aam48537 Anti-infl
40	36	90.0	6	5	AAM48548	Aam48548 Anti-infl
41	36	90.0	6	5	AAM48559	Aam48559 Anti-infl
42	36	90.0	6	5	AAM48509	Aam48509 NBD mutan
43	36	90.0	6	5	AAM48510	Aam48510 NBD mutan
44	36	90.0	6	5	AAM48536	Aam48536 Anti-infl
45	36	90.0	6	6	ABU08420	Abu08420 Human NEM
46	36	90.0	6	6	ABU08421	Abu08421 Human NEM
47	36	90.0	6	6	ADA61778	Ada61778 IKKbeta N
48	36	90.0	6	6	ADA61812	Ada61812 NFkB esse
49	36	90.0	6	6	ADA61811	Ada61811 NFkB esse
50	36	90.0	6	6	ADA61813	Ada61813 NFkB esse

ALIGNMENTS

RESULT 1
AAM48538
ID AAM48538 standard; peptide; 6 AA.
XX
AC AAM48538;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 41.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX)
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 61; 88pp; English.

XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 40; DB 5; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 2
AAM48570
ID AAM48570 standard; peptide; 6 AA.
XX
AC AAM48570;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 73.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 40; DB 5; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 3
ADA61814
ID ADA61814 standard; peptide; 6 AA.
XX
AC ADA61814;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #14.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.

PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 40; DB 6; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 4
ADA61846
ID ADA61846 standard; peptide; 6 AA.
XX
AC ADA61846;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #46.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 6 AA;

Query Match 100.0%; Score 40; DB 6; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 5
AAM48574
ID AAM48574 standard; peptide; 7 AA.
XX
AC AAM48574;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 77.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially

```
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 7 AA;

  Query Match             100.0%;  Score 40;  DB 5;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          1 ADWSWA 6


RESULT 6
ADA61850
ID   ADA61850 standard; peptide; 7 AA.
XX
AC   ADA61850;
XX
DT   20-NOV-2003  (first entry)
XX
DE   NFkB essential modulator (NEMO) binding peptide #50.
XX
KW   NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW   antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW   antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW   dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW   gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW   psoriasis; rheumatoid arthritis; osteoarthritis;
KW   inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW   systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW   Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW   necrosis factor kappa B essential modulator.
XX
OS   Unidentified.
XX
PN   US2003054999-A1.
XX
PD   20-MAR-2003.
XX
PF   02-MAY-2001; 2001US-00847946.
XX
PR   02-MAY-2000; 2000US-0201261P.
XX
PA   (MAYM/) MAY M J.
PA   (GHOS/) GHOSH S.
PA   (FIND/) FINDEIS M A.
PA   (PHIL/) PHILLIPS K.
PA   (HANN/) HANNIG G.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K,  Hannig G;
XX
DR   WPI; 2003-596541/56.
XX
PT   New compound for diagnosing or treating inflammatory disorders, e.g.
PT   asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT   cancer, comprises a membrane translocation domain and a NEMO binding
PT   sequence.
XX
PS   Claim 6; Page 23; 37pp; English.
XX
CC   The invention describes an anti-inflammatory compound comprising (I). The
CC   compound is useful for diagnosing or treating inflammatory disorders,
CC   such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC   inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC   systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC   Alzheimer's disease or viral infection. This is the amino acid sequence
CC   of an anti-iflammatory peptide that binds to, and down-regulates,
CC   necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ   Sequence 7 AA;

  Query Match             100.0%;  Score 40;  DB 6;  Length 7;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          1 ADWSWA 6


RESULT 7
AAM48575
ID   AAM48575 standard; peptide; 8 AA.
XX
AC   AAM48575;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 78.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 62; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
```

CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 8 AA;

Query Match 100.0%; Score 40; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 8
AAM48567
ID AAM48567 standard; peptide; 8 AA.
XX
AC AAM48567;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 70.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 8 AA;

Query Match 100.0%; Score 40; DB 5; Length 8;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 3 ADWSWA 8

RESULT 9
ADA61851
ID ADA61851 standard; peptide; 8 AA.
XX
AC ADA61851;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #51.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;

XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 8 AA;

```
  Query Match             100.0%;  Score 40;  DB 6;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          1 ADWSWA 6
```

RESULT 10
ADA61843
ID ADA61843 standard; peptide; 8 AA.
XX
AC ADA61843;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #43.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 8 AA;

```
  Query Match             100.0%;  Score 40;  DB 6;  Length 8;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          3 ADWSWA 8
```

RESULT 11
AAM48573
ID AAM48573 standard; peptide; 9 AA.
XX
AC AAM48573;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 76.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The

```
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 9 AA;

  Query Match             100.0%;  Score 40;  DB 5;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          2 ADWSWA 7


RESULT 12
AAM48566
ID   AAM48566 standard; peptide; 9 AA.
XX
AC   AAM48566;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 69.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 62; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 9 AA;

  Query Match             100.0%;  Score 40;  DB 5;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          1 ADWSWA 6


RESULT 13
AAM48569
ID   AAM48569 standard; peptide; 9 AA.
XX
AC   AAM48569;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 72.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
```

PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 40; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 14
AAM48572
ID AAM48572 standard; peptide; 9 AA.
XX
AC AAM48572;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 75.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX

DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 40; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 3 ADWSWA 8

RESULT 15
ADA61848
ID ADA61848 standard; peptide; 9 AA.
XX
AC ADA61848;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #48.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.

PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 40; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 3 ADWSWA 8

RESULT 16
ADA61841
ID ADA61841 standard; peptide; 9 AA.
XX
AC ADA61841;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #41.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 40; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 17
ADA61849
ID ADA61849 standard; peptide; 9 AA.
XX
AC ADA61849;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #49.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.

PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 40; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 2 ADWSWA 7

RESULT 18
ADA61845
ID ADA61845 standard; peptide; 9 AA.
XX
AC ADA61845;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #45.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 9 AA;

Query Match 100.0%; Score 40; DB 6; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 1 ADWSWA 6

RESULT 19
ADA61842
ID ADA61842 standard; peptide; 9 AA.
XX
AC ADA61842;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #42.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.

```
CC   systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC   Alzheimer's disease or viral infection. This is the amino acid sequence
CC   of an anti-iflammatory peptide that binds to, and down-regulates,
CC   necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ   Sequence 9 AA;

  Query Match             100.0%;  Score 40;  DB 6;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          1 ADWSWA 6


RESULT 20
AAM48568
ID   AAM48568 standard; peptide; 10 AA.
XX
AC   AAM48568;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 71.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 62; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 10 AA;

  Query Match             100.0%;  Score 40;  DB 5;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 2.6;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          2 ADWSWA 7


RESULT 21
AAM48571
ID   AAM48571 standard; peptide; 10 AA.
XX
AC   AAM48571;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 74.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 62; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
```

CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 40; DB 5; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 3 ADWSWA 8

RESULT 22
ADA61844
ID ADA61844 standard; peptide; 10 AA.
XX
AC ADA61844;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #44.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 40; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 2 ADWSWA 7

RESULT 23
ADA61847
ID ADA61847 standard; peptide; 10 AA.
XX
AC ADA61847;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #47.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence

CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 10 AA;

Query Match 100.0%; Score 40; DB 6; Length 10;
Best Local Similarity 100.0%; Pred. No. 2.6;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 3 ADWSWA 8

RESULT 24
AAM48565
ID AAM48565 standard; peptide; 11 AA.
XX
AC AAM48565;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 68.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 62; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 11 AA;

Query Match 100.0%; Score 40; DB 5; Length 11;
Best Local Similarity 100.0%; Pred. No. 2.9;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||||
Db 3 ADWSWA 8

RESULT 25
ADA61840
ID ADA61840 standard; peptide; 11 AA.
XX
AC ADA61840;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #40.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,

```
CC   necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ   Sequence 11 AA;

  Query Match             100.0%;  Score 40;  DB 6;  Length 11;
  Best Local Similarity   100.0%;  Pred. No. 2.9;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              ||||||
Db          3 ADWSWA 8


RESULT 26
AAU21305
ID   AAU21305 standard; protein; 33 AA.
XX
AC   AAU21305;
XX
DT   18-DEC-2001  (first entry)
XX
DE   Human novel foetal antigen, SEQ ID NO 1549.
XX
KW   Human; foetal tissue antigen; antiinflammatory; neuroprotective;
KW   immunomodulator; cardiovascular; cytostatic; nephrothropic;
KW   cardiovascular; autoimmune disease; rheumatoid arthritis;
KW   hyperproliferative disorder; breast neoplasm; cancer;
KW   cardiovascular disorder; cardiac arrest; cerebrovascular disorder;
KW   cerebral ischaemia; angiogenesis; nervous system disorder;
KW   Alzheimer's disease; infection; ocular disorder; corneal infection;
KW   wound healing; epithelial cell proliferation; food additive.
XX
OS   Homo sapiens.
XX
PN   WO200155312-A2.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001321.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231368P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
PR   20-OCT-2000; 2000US-0241787P.
PR   20-OCT-2000; 2000US-0241808P.
PR   20-OCT-2000; 2000US-0241809P.
PR   20-OCT-2000; 2000US-0241826P.
PR   01-NOV-2000; 2000US-0244617P.
PR   08-NOV-2000; 2000US-0246474P.
PR   08-NOV-2000; 2000US-0246475P.
PR   08-NOV-2000; 2000US-0246476P.
PR   08-NOV-2000; 2000US-0246477P.
PR   08-NOV-2000; 2000US-0246478P.
PR   08-NOV-2000; 2000US-0246523P.
PR   08-NOV-2000; 2000US-0246524P.
PR   08-NOV-2000; 2000US-0246525P.
PR   08-NOV-2000; 2000US-0246526P.
PR   08-NOV-2000; 2000US-0246527P.
PR   08-NOV-2000; 2000US-0246528P.
PR   08-NOV-2000; 2000US-0246532P.
PR   08-NOV-2000; 2000US-0246609P.
PR   08-NOV-2000; 2000US-0246610P.
PR   08-NOV-2000; 2000US-0246611P.
PR   08-NOV-2000; 2000US-0246613P.
PR   17-NOV-2000; 2000US-0249207P.
PR   17-NOV-2000; 2000US-0249208P.
```

PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-488782/53.
DR N-PSDB; AAS34125.
XX
PT New polynucleotides and polypeptides for diagnosing, treating, preventing
PT or prognosing e.g. diseases or disorders of the nervous, musculoskeletal,
PT excretory, gastrointestinal, reproductive, and respiratory systems.
XX
PS Claim 11; SEQ ID NO 1549; 642pp; English.
XX
CC The invention relates to novel nucleic acids encoding novel human foetal
CC antigens. The nucleic acids and proteins are used to prevent, treat (e.g.
CC by gene therapy) or ameliorate a medical condition in e.g. humans, mice,
CC rabbits, goats, horses, cats, dogs, chickens or sheep. They are also used
CC in diagnosing a pathological condition or susceptibility to a
CC pathological condition. The antibodies to the antigens can also be used
CC in alleviating symptoms associated with the disorders and in diagnostic
CC immunoassays e.g. radioimmunoassays or enzyme linked immunosorbent assays
CC (ELISA). Disorders which are diagnosed or treated include autoimmune
CC diseases e.g. rheumatoid arthritis, hyperproliferative disorders e.g.
CC neoplasms of the breast or liver, cardiovascular disorders e.g. cardiac
CC arrest, cerebrovascular disorders e.g. cerebral ischaemia, angiogenesis,
CC nervous system disorders e.g. Alzheimer's disease, infections caused by
CC bacteria, viruses and fungi and ocular disorders e.g. corneal infection.
CC The polypeptides can also be used to aid wound healing and epithelial
CC cell proliferation, to prevent skin aging due to sunburn, to maintain
CC organs before transplantation, for supporting cell culture of primary
CC tissues, to regenerate tissues and in chemotaxis. The polypeptides can
CC also be used as a food additive or preservative to increase or decrease
CC storage capabilities, fat content, lipid, protein, carbohydrate,
CC vitamins, minerals, cofactors and other nutritional components. Numerous
CC examples of diseases and disorders treated by the nucleic acids and
CC proteins are given in the specification. The present sequence represents
CC a foetal antigen of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained

Query Match 92.5%; Score 37; DB 4; Length 33;
Best Local Similarity 83.3%; Pred. No. 27;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||| :||
Db 9 ADWTWA 14

RESULT 27
AAY06332
ID AAY06332 standard; protein; 103 AA.
XX
AC AAY06332;
XX
DT 17-OCT-2003 (revised)
DT 06-SEP-1999 (first entry)
XX
DE Gliocladium roseum EGIII-like cellulase (partial sequence).
XX
KW Cellulase; endoglucanase; EGIII; textile; feed additive; baking;
KW food processing; grain wet milling; pulp; paper.
XX
OS Bionectria ochroleuca.
XX
PN WO9931255-A2.
XX
PD 24-JUN-1999.
XX
PF 14-DEC-1998; 98WO-US026552.
XX
PR 16-DEC-1997; 97US-00991720.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Bower BS, Fowler T, Phillips JI;
XX
DR WPI; 1999-395187/33.
XX
PT EGIII like cellulase enzyme with cellulolytic activity contains specific
PT amino acid string, useful for treatment of cellulose textile, as feed
PT additive, in wood pulp treatment, reduction of biomass to glucose, or as
PT laundry detergent.
XX
PS Example; Fig 3; 47pp; English.
XX
CC The present polypeptide represents a partial sequence of a novel EGIII-
CC like cellulase of Gliocladium roseum. It was deduced from a partial gene
CC sequence isolated from genomic DNA using PCR primers (see AAX59180-91)
CC based on conserved motifs (see AAY06325-29) of Trichoderma reesei EGIII
CC cellulase and related enzymes. PCR has been used to identify novel EGIII-
CC like enzymes, including the present polypeptide, from bacterial and
CC fungal sources (see AAY06331-70). Also provided by the invention are
CC vectors, host cells and methods for the recombinant production of such
CC enzymes, which can be used in the treatment of cellulose-containing
CC textiles, as feed additives, in the treatment of wood pulp, in the
CC reduction of biomass to glucose, in the stone washing of indigo dyed
CC denim, or as laundry detergent components (all claimed). (Updated on 17-
CC OCT-2003 to standardise OS field)
XX
SQ Sequence 103 AA;

Query Match 92.5%; Score 37; DB 2; Length 103;
Best Local Similarity 83.3%; Pred. No. 91;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
|||||:
Db 29 ADWSWS 34

RESULT 28
AAY06363
ID AAY06363 standard; protein; 236 AA.
XX
AC AAY06363;

XX
DT 27-AUG-2003 (revised)
DT 06-SEP-1999 (first entry)
XX
DE Gliocladium roseum EGIII-like cellulase.
XX
KW Cellulase; endoglucanase; EGIII; textile; feed additive; baking;
KW food processing; grain wet milling; pulp; paper.
XX
OS Bionectra ochrroleuca.
XX
PN WO9931255-A2.
XX
PD 24-JUN-1999.
XX
PF 14-DEC-1998; 98WO-US026552.
XX
PR 16-DEC-1997; 97US-00991720.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Bower BS, Fowler T, Phillips JI;
XX
DR WPI; 1999-395187/33.
XX
PT EGIII like cellulase enzyme with cellulolytic activity contains specific
PT amino acid string, useful for treatment of cellulose textile, as feed
PT additive, in wood pulp treatment, reduction of biomass to glucose, or as
PT laundry detergent.
XX
PS Example; Fig 6; 47pp; English.
XX
CC The present polypeptide represents a full-length sequence of a novel
CC EGIII-like cellulase of Gliocladium roseum. It was deduced from a gene
CC sequence isolated from genomic DNA using PCR primers (see AAX59180-91)
CC based on conserved motifs (see AAY06325-29) of Trichoderma reesei EGIII
CC cellulase and related enzymes. PCR has been used to identify novel EGIII-
CC like enzymes, including the present protein, from bacterial and fungal
CC sources (see AAY06331-70). The sequence shows homology to T. reesei EGIII
CC (see AAY06330). Also provided by the invention are vectors, host cells
CC and methods for the recombinant production of such enzymes, which can be
CC used in the treatment of cellulose-containing textiles, as feed
CC additives, in the treatment of wood pulp, in the reduction of biomass to
CC glucose, in the stone washing of indigo dyed denim, or as laundry
CC detergent components (all claimed). (Updated on 27-AUG-2003 to correct OS
CC field.)
XX
SQ Sequence 236 AA;

Query Match 92.5%; Score 37; DB 2; Length 236;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
|||||:
Db 63 ADWSWS 68

RESULT 29
AAY84341
ID AAY84341 standard; protein; 236 AA.
XX
AC AAY84341;
XX
DT 12-SEP-2003 (revised)
DT 06-AUG-2003 (revised)
DT 12-JUL-2000 (first entry)
XX
DE Amino acid sequence of an endoglucanase III (EGIII)-like cellulase.
XX
KW Endoglucanase III; EGIII; EGIII-like cellulase; surfactant stability;
KW cellulase; textile processing; textile cleaning; stonewashing;
KW indigo dyed denim; cellulose containing fabric; fabric smoothness;
KW pill removal; fibril removal; cotton; cellulosic fibre; dying; detergent;
KW animal feed; wood pulp; paper; grain; biomass reduction; glucose.
XX
OS Bionectria ochroleuca.
XX
PN WO200014208-A1.
XX
PD 16-MAR-2000.
XX
PF 24-AUG-1999; 99WO-US019154.
XX
PR 03-SEP-1998; 98US-00146729.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Fowler T;
XX
DR WPI; 2000-271052/23.
XX
PT Novel variant endoglucanase III-like cellulases with improved surfactant
PT stability and resistance to temperature stress, useful for textile
PT processing or cleaning, treating wood pulp, food and grain, and reducing
PT biomass to glucose.
XX
PS Disclosure; Page 62; 73pp; English.
XX
CC The present sequence represents an endoglucanase III (EGIII)-like
CC cellulase. The cellulase has homology to the Trichoderma reesei EGIII
CC protein. The variant cellulases have improved temperature stability, and
CC improved surfactant stability. The variant cellulases and compositions
CC containing them are used in textile processing or cleaning, e.g.
CC stonewashing of indigo dyed denim, and modifying the texture, feel or
CC appearance of cellulose containing fabrics (e.g. improving fabric
CC smoothness or removing pills and fibrils). The compositions may also be
CC used for the removal of immature or dead cotton from cellulosic fibres or
CC fabric, which can cause uneven dying. The cellulase may also be used in a
CC detergent composition for washing laundry and dishes and in the treatment
CC of animal feed, wood pulp, paper, non-animal foods and grains. The
CC enzymes may also be used in the reduction of biomass to glucose. (Updated
CC on 06-AUG-2003 to correct OS field.) (Updated on 12-SEP-2003 to
CC standardise OS field)
XX
SQ Sequence 236 AA;

Query Match 92.5%; Score 37; DB 3; Length 236;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
|||||:
Db 63 ADWSWS 68

RESULT 30
AAB14876
ID AAB14876 standard; protein; 236 AA.
XX
AC AAB14876;
XX
DT 12-SEP-2003 (revised)
DT 21-NOV-2000 (first entry)
XX
DE Gliocladium roseum (3) EGIII-like cellulase.
XX
KW Gliocladium roseum; Trichoderma reesei; endoglucanase III; EGIII;
KW cellulase; mutant; enzyme stability; textile treatment;
KW wood pulp treatment; feed additive; detergent.
XX
OS Bionectria ochroleuca.
XX
PN WO200037614-A2.
XX
PD 29-JUN-2000.

XX
PF 12-NOV-1999; 99WO-US026704.
XX
PR 18-DEC-1998; 98US-00216295.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Mitchinson C, Wendt DJ;
XX
DR WPI; 2000-482483/42.
XX
PT Novel endoglucanase III or endoglucanase III-like cellulase useful for
PT treating textiles and wood pulp comprises a substitution or deletion at
PT specified positions in the wild form of endoglucanase III.
XX
PS Example 1; Fig 3; 52pp; English.
XX
CC The present sequence is a cellulase related to endoglucanase III (EGIII)
CC from Trichoderma reesei. EGIII-like genes were isolated from genomic DNA
CC libraries constructed from various microorganisms by PCR. The isolated
CC genes showed significant homology to EGIII from T. reesei. Certain
CC subsitution and deletion mutations have been incorporated into EGIII and
CC EGIII-like cellulases to produce variant enzymes with improved stability,
CC e.g. increased resistance to temperature stress. The mutants may be used
CC in textile and wood pulp treatment, as a feed additive, and for reducing
CC biomass to glucose. They are also useful for stonewashing or indigo dyed
CC denim and as an agent in laundry and dish detergents. (Updated on 12-SEP-
CC 2003 to standardise OS field)
XX
SQ Sequence 236 AA;

Query Match 92.5%; Score 37; DB 3; Length 236;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||:
Db 63 ADWSWS 68

RESULT 31
AAU77584
ID AAU77584 standard; protein; 236 AA.
XX
AC AAU77584;
XX
DT 29-AUG-2003 (revised)
DT 05-JUN-2002 (first entry)
XX
DE G. roseum EGIII-like cellulase #3.
XX
KW EGIII; cellulase; endoglucanase III; detergent; cellulose treatment;
KW stonewashing; indigo dyed denim; feed additive; wood pulp treatment;
KW biomass reduction; laundry; dish detergent; milling; depilling;
KW softening; surface fibre removal; anti-greying.
XX
OS Bionectria ochroleuca.
XX
PN WO200212466-A2.
XX
PD 14-FEB-2002.
XX
PF 31-JUL-2001; 2001WO-US023991.
XX
PR 04-AUG-2000; 2000US-00633085.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Day AG, Gualfetti P, Mitchinson C, Shaw A;
XX
DR WPI; 2002-241752/29.
XX
PT Novel variant of endoglucanase III or endoglucanase III-like cellulase
PT for treating cellulose containing textile, has performance sensitive
PT residues replaced to residue having modified stability.
XX
PS Example 1; Fig 3; 47pp; English.
XX
CC The invention relates to a variant of endoglucanase III (EGIII) or EGIII-
CC like cellulase comprising a substitution or deletion at a position
CC corresponding to one or more of residues W7, G31, A35, T145, Y147, Q162
CC and/or Y168 in EGIII from Trichoderma reesei. Also included are a DNA
CC encoding the variant, a vector comprising the DNA, a host cell
CC transformed with the vector and a detergent composition comprising a
CC surfactant and the variant. The variant is useful in the treatment of a
CC cellulose containing textile, stonewashing or indigo dyed denim or as a
CC feed additive or in the treatment of wood pulp, in reduction of biomass
CC to glucose. The detergent composition is useful as the main component of
CC a laundry or dish detergent and is further useful as pre-wash
CC composition, pre-soak composition or for cleaning during the regular wash
CC or clean cycle. The variant increases value of animal feed, improves the
CC drainability of food pulp, enhances food products and reduces fibre in
CC grain during grain wet (or dry) milling process. Further cellulase
CC improves the feel e.g. smoothness and/or appearance e.g. removing pills
CC and fibrils which tend to reduce the sharpness in appearance of a fabric,
CC of cellulose containing fabric, and imparts desirable effects such as
CC depilling, softening, anti-pilling, surface fiber removal, anti-greying
CC and cleaning. The present sequence represents an EGIII-like cellulase
CC with homology to that of the T. reesei protein, encoded by a gene
CC isolated by the primers appearing as ABK11339-ABK11349. (Updated on 29-
CC AUG-2003 to standardise OS field)
XX
SQ Sequence 236 AA;

Query Match 92.5%; Score 37; DB 5; Length 236;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||:
Db 63 ADWSWS 68

RESULT 32
AAU77428
ID AAU77428 standard; protein; 236 AA.
XX
AC AAU77428;
XX
DT 29-AUG-2003 (revised)
DT 05-JUN-2002 (first entry)
XX
DE Gliocladium roseum EGIII-like cellulase #3.
XX
KW Endoglucanase III-like cellulase; EGIII-like;
KW cellulose containing textile; enzyme.
XX
OS Bionectria ochroleuca.
XX
PN WO200212464-A2.
XX
PD 14-FEB-2002.
XX
PF 31-JUL-2001; 2001WO-US023989.
XX
PR 04-AUG-2000; 2000US-00632426.
XX
PA (GEMV) GENENCOR INT INC.
XX
PI Mitchinson C, Ropp TH, Swanson BA;
XX
DR WPI; 2002-241750/29.
XX
PT Novel endoglucanase III (EGIII)-like cellulase variant comprising
PT substitution/deletion at positions corresponding to specific residues in
PT EGIII from Trichoderma reesei, useful for treating cellulose containing

PT textile.
XX
PS Example 1; Fig 3; 41pp; English.
XX
CC The present invention relates to novel endoglucanase III (EGIII)-like
CC cellulase variants which comprise a substitution or deletion at a
CC position corresponding to one or more of residues M79, M154 and/or M118
CC in mature EGIII from the fungus, Trichoderma reesei. The variants are
CC useful in the treatment of a cellulose containing textile. By
CC substituting other amino acids for the native methionines at positions
CC 79, 118 and 154 (sites where oxidation of the enzyme takes place) in
CC EGIII from T. reesei, oxidatively more stable enzymes are obtained. The
CC present sequence represents Gliocladium roseum EGIII-like cellulase #3.
CC (Updated on 29-AUG-2003 to standardise OS field)
XX
SQ Sequence 236 AA;

Query Match 92.5%; Score 37; DB 5; Length 236;
Best Local Similarity 83.3%; Pred. No. 2.2e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||| :
Db 63 ADWSWS 68

RESULT 33
ABP65718
ID ABP65718 standard; protein; 274 AA.
XX
AC ABP65718;
XX
DT 19-NOV-2002 (first entry)
XX
DE Bifidobacterium longum NCC2705 ORF amino acid sequence SEQ ID NO:462.
XX
KW Bifidobacterium longum NCC2705; Bifidobacterium; bacterial;
KW antidiarrheic; antibacterial; inhibitor of Salmonella; detection;
KW identification; lactic acid bacterium; diarrhoea; pathogenic bacteria;
KW rotavirus; food composition; pharmaceutical composition.
XX
OS Bifidobacterium longum.
XX
PN EP1227152-A1.
XX
PD 31-JUL-2002.
XX
PF 30-JAN-2001; 2001EP-00102050.
XX
PR 30-JAN-2001; 2001EP-00102050.
XX
PA (NEST) SOC PROD NESTLE SA.
XX
DR WPI; 2002-668397/72.
XX
PT Novel polynucleotide comprising Bifidobacterium genome sequence useful as
PT a probe or primer for detecting and/or identifying Bifidobacterium longum
PT in a biological sample.
XX
PS Claim 3; SEQ ID NO 462; 80pp; English.
XX
CC The present invention describes a polynucleotide (I) comprising a
CC sequence of a Bifidobacterium genome selected from the nucleotide
CC sequences given in ABQ81842 and ABQ81843, or a sequence exhibiting at
CC least 90% identity or which hybridises with the sequences given in
CC ABQ81842 and ABQ81843. Also described is a polynucleotide (II) encoding a
CC fusion protein, comprising a sequence selected from 1097 sequences given
CC in ABP65258 to ABP66354 ligated in frame to a polynucleotide encoding a
CC heterologous polypeptide. (I) has antidiarrheic and antibacterial
CC activities, and can be used as an inhibitor of Salmonella. (I) (which is
CC a probe) is useful for the detection and/or identification of
CC Bifidobacterium longum in a biological sample. A carrier containing the
CC lactic acid bacterium Bifidobacterium longum NCC2705 (CNCM I-2618) can be
CC used for preventing and/or treating diarrhoea brought about by pathogenic
CC bacteria and/or rotavirus. The carrier is a food composition selected
CC from milk, yogurt, curd, cheese, fermented milks, milk based fermented
CC products, ice-creams, fermented cereal based products, milk based
CC powders, infant formula, pet food or a pharmaceutical composition
CC selected from tablets, liquid bacterial suspensions, dried oral
CC supplement, wet oral supplement, dry tube feeding or wet tube feeding.
CC (I) is useful in DNA arrays or chips to carry out analysis of the
CC expression of the Bifidobacterium gene. ABQ81844 to ABQ81850 represent
CC Bifidobacterium related nucleotide sequences given in the Sequence
CC Listing from the present invention but not mentioned further within the
CC specification. N.B. The sequence data for this patent is not represented
CC in the printed specification but is based on sequence information
CC supplied by the European Patent Office
XX
SQ Sequence 274 AA;

Query Match 92.5%; Score 37; DB 5; Length 274;
Best Local Similarity 83.3%; Pred. No. 2.6e+02;
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 ADWSWA 6
||||| :
Db 171 ADWSWS 176

RESULT 34
ABB62635
ID ABB62635 standard; protein; 597 AA.
XX
AC ABB62635;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 14697.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US009231.
XX
PR 23-MAR-2000; 2000US-0191637P.
PR 11-JUL-2000; 2000US-00614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI; 2001-656860/75.
DR N-PSDB; ABL06738.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signaling and cell-cell
PT interactions.
XX
PS Disclosure; SEQ ID NO 14697; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC ABB72072). The sequence data for this patent did not form part of the
CC printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences

```
XX
SQ   Sequence 597 AA;

  Query Match             92.5%;  Score 37;  DB 4;  Length 597;
  Best Local Similarity   83.3%;  Pred. No. 5.8e+02;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              :|||||
Db        158 SDWSWA 163


RESULT 35
AAU33594
ID   AAU33594 standard; protein; 885 AA.
XX
AC   AAU33594;
XX
DT   14-FEB-2002  (first entry)
XX
DE   Pseudomonas aeruginosa cellular proliferation protein #38.
XX
KW   Antisense; prokaryotic cellular proliferation protein; antibiotic;
KW   antibacterial; drug design.
XX
OS   Pseudomonas aeruginosa.
XX
PN   WO200170955-A2.
XX
PD   27-SEP-2001.
XX
PF   21-MAR-2001; 2001WO-US009180.
XX
PR   21-MAR-2000; 2000US-0191078P.
PR   23-MAY-2000; 2000US-0206848P.
PR   26-MAY-2000; 2000US-0207727P.
PR   23-OCT-2000; 2000US-0242578P.
PR   27-NOV-2000; 2000US-0253625P.
PR   22-DEC-2000; 2000US-0257931P.
PR   16-FEB-2001; 2001US-0269308P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Haselbeck R,  Ohlsen KL,  Zyskind JW,  Wall D,  Trawick JD,  Carr GJ;
PI   Yamamoto RT,  Xu HH;
XX
DR   WPI; 2001-611495/70.
DR   N-PSDB; AAS51453.
XX
PT   New polynucleotides for the identification and development of
PT   antibiotics, comprise sequences of antisense nucleic acids.
XX
PS   Example 3; SEQ ID NO 5090; 511pp; English.
XX
CC   The invention relates to antisense inhibitors of genes essential to
CC   prokaryotic cellular proliferation, their use in identifying the genes,
CC   their use in the discovery of novel antibiotics, the essential genes
CC   themselves and the encoded proteins. The prokaryotes used are Escherichia
CC   coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae,
CC   Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also
CC   useful for the identification of potential new targets for antibiotic
CC   development. The antisense nucleic acids can also be used to identify
CC   proteins used in proliferation, to express these proteins, and to obtain
CC   antibodies capable of binding to the expressed proteins. The proteins can
CC   be used to screen compounds in rational drug discovery programmes. The
CC   antisense nucleic acid sequence is also useful to screen for homologous
CC   nucleic acids which are required for cell proliferation in a wide variety
CC   of organisms. The present sequence represents an essential prokaryotic
CC   cellular proliferation protein. Note: The sequence data for this patent
CC   did not form part of the printed specification, but was obtained in
CC   electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 885 AA;

  Query Match             92.5%;  Score 37;  DB 4;  Length 885;
  Best Local Similarity   83.3%;  Pred. No. 8.8e+02;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              |||:||
Db        563 ADWAWA 568


RESULT 36
ABU15648
ID   ABU15648 standard; protein; 885 AA.
XX
AC   ABU15648;
XX
DT   19-JUN-2003  (first entry)
XX
DE   Protein encoded by Prokaryotic essential gene #1175.
XX
KW   Antisense; prokaryotic essential gene; cell proliferation; drug design.
XX
OS   Pseudomonas aeruginosa.
XX
PN   WO200277183-A2.
XX
PD   03-OCT-2002.
XX
PF   21-MAR-2002; 2002WO-US009107.
XX
PR   21-MAR-2001; 2001US-00815242.
PR   06-SEP-2001; 2001US-00948993.
PR   25-OCT-2001; 2001US-0342923P.
PR   08-FEB-2002; 2002US-00072851.
PR   06-MAR-2002; 2002US-0362699P.
XX
PA   (ELIT-) ELITRA PHARM INC.
XX
PI   Wang L,  Zamudio C,  Malone C,  Haselbeck R,  Ohlsen KL,  Zyskind JW;
PI   Wall D,  Trawick JD,  Carr GJ,  Yamamoto R,  Forsyth RA,  Xu HH;
XX
DR   WPI; 2003-029926/02.
DR   N-PSDB; ACA19518.
XX
PT   New antisense nucleic acids, useful for identifying proteins or screening
PT   for homologous nucleic acids required for cellular proliferation to
PT   isolate candidate molecules for rational drug discovery programs.
XX
PS   Claim 25; SEQ ID NO 43572; 1766pp; English.
XX
CC   The invention relates to an isolated nucleic acid comprising any one of
CC   the 6213 antisense sequences given in the specification where expression
CC   of the nucleic acid inhibits proliferation of a cell. Also included are:
CC   (1) a vector comprising a promoter operably linked to the nucleic acid
CC   encoding a polypeptide whose expression is inhibited by the antisense
CC   nucleic acid; (2) a host cell containing the vector; (3) an isolated
CC   polypeptide or its fragment whose expression is inhibited by the
CC   antisense nucleic acid; (4) an antibody capable of specifically binding
CC   the polypeptide;(5) producing the polypeptide; (6) inhibiting cellular
CC   proliferation or the activity of a gene in an operon required for
CC   proliferation; (7) identifying a compound that influences the activity of
CC   the gene product or that has an activity against a biological pathway
CC   required for proliferation, or that inhibits cellular proliferation; (8)
CC   identifying a gene required for cellular proliferation or the biological
CC   pathway in which a proliferation-required gene or its gene product lies
CC   or a gene on which the test compound that inhibits proliferation of an
CC   organism acts; (9) manufacturing an antibiotic; (10) profiling a
CC   compound's activity; (11) a culture comprising strains in which the gene
CC   product is overexpressed or underexpressed; (12) determining the extent
CC   to which each of the strains is present in a culture or collection of
CC   strains; or (13) identifying the target of a compound that inhibits the
CC   proliferation of an organism. The antisense nucleic acids are useful for
```

```
CC   identifying proteins or screening for homologous nucleic acids required
CC   for cellular proliferation to isolate candidate molecules for rational
CC   drug discovery programs, or for screening homologous nucleic acids
CC   required for proliferation in cells other than S. aureus, S. typhimurium,
CC   K. pneumoniae or P. aeruginosa. The present sequence is encoded by one of
CC   the target prokaryotic essential genes. Note: The sequence data for this
CC   patent did not form part of the printed specification, but was obtained
CC   in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 885 AA;

  Query Match             92.5%;  Score 37;  DB 6;  Length 885;
  Best Local Similarity   83.3%;  Pred. No. 8.8e+02;
  Matches    5;  Conservative    1;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSWA 6
              |||:||
Db        563 ADWAWA 568


RESULT 37
ABB08727
ID   ABB08727 standard; peptide; 6 AA.
XX
AC   ABB08727;
XX
DT   14-JUN-2002  (first entry)
XX
DE   Mutated IKKbeta NEMO binding domain peptide SEQ ID NO 4.
XX
KW   IKKbeat; IKKalpha; NEMO; NEMO binding domain; NBD; NF-kappaB; NF-kB;
KW   kinase activation; leukocyte; inflammation; E-selectin; osteoclast;
KW   autoimmune disease; transplant rejection; osteoporosis; cancer;
KW   Alzheimer's disease; viral; infection; asthma; anaphylaxis; psoriasis;
KW   rheumatoid arthritis; Crohn's disease; multiple sclerosis; HIV;
KW   corticosteroid; immunosuppression; antiinflammatory; immunosuppressive;
KW   osteopathic; cytostatic; nootropic; neuroprotective; anti-HIV; human;
KW   antiarteriosclerotic; virucide; antiasthmatic; antiallergic;
KW   dermatological; antibacterial; antipsoriatic; antirheumatic;
KW   antiarthritic; osteopathic; antiulcer; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 1
FT                   /note= "Wildtype Leu substituted by Ala"
XX
PN   WO200183547-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US040654.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S;
XX
DR   WPI; 2002-179350/23.
XX
PT   Modulating NF-kappaB induction in a cell, useful for treating e.g.
PT   inflammatory disorders, osteoporosis and cancer, comprises contacting a
PT   cell with an anti-inflammatory compound comprising at least one NEMO
PT   binding domain.
XX
PS   Claim 23; Page 44; 82pp; English.
XX
CC   The invention relates to modulating NF-kappaB (NF-kB) induction in a cell
CC   comprises contacting a cell with an anti-inflammatory compound (ABB08725-
CC   ABB08742) comprising at least one NEMO binding domain (ABB77313). The
CC   compound has acts through selective inhibition of cytokine-mediated NF-kB
CC   activation by blocking the interaction of NEMO with IKKbeta at the NEMO
CC   binding domain. Blockage of IKKbeta-NEMO interaction results in
CC   inhibition of IKKbeta kinase activation and subsequent decreased
CC   phosphorylation of IkappaB. The compound may also act (directly or
CC   indirectly) by blocking the recruitment of leukocytes into sites of acute
CC   and chronic inflammation, by down-regulating the expression of E-selectin
CC   on leukocytes or by blocking osteoclast differentiation. The compound is
CC   useful in treating NF-kB mediated conditions, where the condition is an
CC   inflammatory disorder, an autoimmune disease, transplant rejection,
CC   osteoporosis, cancer, Alzheimer's disease, atherosclerosis, a viral
CC   infection or ataxia telangiectasia. The inflammatory disorder is asthma,
CC   allergies, urticaria, anaphylaxis, cutaneous inflammation, sepsis,
CC   psoriasis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis,
CC   inflammatory bowel disease, chronic obstructive pulmonary disease,
CC   vasculitis and bursitis. The inflammatory disorder may also be
CC   dermatitis, eczema, psoriasis, osteoarthritis, psoriatic arthritis, lupus
CC   and spondylarthritis. Also for Crohn's disease, ulcerative colitis,
CC   polymyalgia, scleroderma, Wegner's granulomatosis, temporal arteritis,
CC   cryoglobulinaemia or multiple sclerosis. For chronic viral infections
CC   caused by Epstein-barr, cytomegalovirus or herpes simplex. Other viral
CC   diseases include HIV and influenza. The compound may also be useful for
CC   treating anaphylaxis, drug and food sensitivity, contact dermatitis,
CC   sunburn or aging. The compound may be used to replace corticosteroids in
CC   any application in which corticosteroids are used, including
CC   immunosuppression in transplants and cancer therapy. Also for identifying
CC   antiinflammatory compounds and for diagnosis of an inflammatory disorder.
CC   The compound may be administered alone or in combination with other known
CC   anti-inflammatory agents. The present sequence is that of a mutated NEMO
CC   binding domain of IKKbeta
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 5;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 38
ABB08728
ID   ABB08728 standard; peptide; 6 AA.
XX
AC   ABB08728;
XX
DT   14-JUN-2002  (first entry)
XX
DE   Mutated IKKbeta NEMO binding domain peptide SEQ ID NO 5.
XX
KW   IKKbeat; IKKalpha; NEMO; NEMO binding domain; NBD; NF-kappaB; NF-kB;
KW   kinase activation; leukocyte; inflammation; E-selectin; osteoclast;
KW   autoimmune disease; transplant rejection; osteoporosis; cancer;
KW   Alzheimer's disease; viral; infection; asthma; anaphylaxis; psoriasis;
KW   rheumatoid arthritis; Crohn's disease; multiple sclerosis; HIV;
KW   corticosteroid; immunosuppression; antiinflammatory; immunosuppressive;
KW   osteopathic; cytostatic; nootropic; neuroprotective; anti-HIV; human;
KW   antiarteriosclerotic; virucide; antiasthmatic; antiallergic;
KW   dermatological; antibacterial; antipsoriatic; antirheumatic;
KW   antiarthritic; osteopathic; antiulcer; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
FH   Key             Location/Qualifiers
FT   Misc-difference 6
FT                   /note= "Wildtype Leu substituted by Ala"
XX
PN   WO200183547-A2.
XX
```

PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US040654.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S;
XX
DR WPI; 2002-179350/23.
XX
PT Modulating NF-kappaB induction in a cell, useful for treating e.g.
PT inflammatory disorders, osteoporosis and cancer, comprises contacting a
PT cell with an anti-inflammatory compound comprising at least one NEMO
PT binding domain.
XX
PS Claim 23; Page 44; 82pp; English.
XX
CC The invention relates to modulating NF-kappaB (NF-kB) induction in a cell
CC comprises contacting a cell with an anti-inflammatory compound (ABB08725-
CC ABB08742) comprising at least one NEMO binding domain (ABB77313). The
CC compound has acts through selective inhibition of cytokine-mediated NF-kB
CC activation by blocking the interaction of NEMO with IKKbeta at the NEMO
CC binding domain. Blockage of IKKbeta-NEMO interaction results in
CC inhibition of IKKbeta kinase activation and subsequent decreased
CC phosphorylation of IkappaB. The compound may also act (directly or
CC indirectly) by blocking the recruitment of leukocytes into sites of acute
CC and chronic inflammation, by down-regulating the expression of E-selectin
CC on leukocytes or by blocking osteoclast differentiation. The compound is
CC useful in treating NF-kB mediated conditions, where the condition is an
CC inflammatory disorder, an autoimmune disease, transplant rejection,
CC osteoporosis, cancer, Alzheimer's disease, atherosclerosis, a viral
CC infection or ataxia telangiectasia. The inflammatory disorder is asthma,
CC allergies, urticaria, anaphylaxis, cutaneous inflammation, sepsis,
CC psoriasis, rheumatoid arthritis, osteoarthritis, psoriatic arthritis,
CC inflammatory bowel disease, chronic obstructive pulmonary disease,
CC vasculitis and bursitis. The inflammatory disorder may also be
CC dermatitis, eczema, psoriasis, osteoarthritis, psoriatic arthritis, lupus
CC and spondylarthritis. Also for Crohn's disease, ulcerative colitis,
CC polymyalgia, scleroderma, Wegner's granulomatosis, temporal arteritis,
CC cryoglobulinaemia or multiple sclerosis. For chronic viral infections
CC caused by Epstein-barr, cytomegalovirus or herpes simplex. Other viral
CC diseases include HIV and influenza. The compound may also be useful for
CC treating anaphylaxis, drug and food sensitivity, contact dermatitis,
CC sunburn or aging. The compound may be used to replace corticosteroids in
CC any application in which corticosteroids are used, including
CC immunosuppression in transplants and cancer therapy. Also for identifying
CC antiinflammatory compounds and for diagnosis of an inflammatory disorder.
CC The compound may be administered alone or in combination with other known
CC anti-inflammatory agents. The present sequence is that of a mutated NEMO
CC binding domain of IKKbeta
XX
SQ Sequence 6 AA;

Query Match 90.0%; Score 36; DB 5; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 DWSWA 6
|||||
Db 2 DWSWA 6

RESULT 39
AAM48537
ID AAM48537 standard; peptide; 6 AA.
XX
AC AAM48537;
XX
DT 20-MAR-2002 (first entry)
XX
DE Anti-inflammatory peptide SEQ ID NO 40.
XX
KW Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW autoimmune disorder; multiple sclerosis; transplant rejection;
KW osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS Synthetic.
XX
PN WO200183554-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US014346.
XX
PR 02-MAY-2000; 2000US-0201261P.
PR 22-AUG-2000; 2000US-00643260.
XX
PA (PRAE-) PRAECIS PHARM INC.
PA (UYYA) UNIV YALE.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K;
XX
DR WPI; 2002-121889/16.
XX
PT Novel antiinflammatory compound comprising membrane translocation domain
PT fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS Claim 6; Page 61; 88pp; English.
XX
CC The invention relates to an antiinflammatory compound (especially
CC AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC antirheumatic, antiarthritic, osteopathic, antibacterial,
CC immunosuppressive, dermatological, neuroprotective, nootropic,
CC antiatherosclerotic, virucide and antiallergic activity. The compounds
CC act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC domain that results in inhibition of IKKbeta kinase activation and
CC subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC viral infections; and ataxia telangiectasia. The compounds are also
CC useful for treating pro-inflammatory responses such as allergies,
CC urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC sunburn, aging and arthritis
XX
SQ Sequence 6 AA;

Query Match 90.0%; Score 36; DB 5; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 DWSWA 6
|||||
Db 2 DWSWA 6

RESULT 40
AAM48548
ID AAM48548 standard; peptide; 6 AA.
XX

```
AC   AAM48548;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 51.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 62; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 5;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5
```

```
RESULT 41
AAM48559
ID   AAM48559 standard; peptide; 6 AA.
XX
AC   AAM48559;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 62.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 62; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 5;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 DWSWA 6
```

```
                  |||||
Db          2 DWSWA 6


RESULT 42
AAM48509
ID   AAM48509 standard; peptide; 6 AA.
XX
AC   AAM48509;
XX
DT   20-MAR-2002  (first entry)
XX
DE   NBD mutant peptide SEQ ID NO 4.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Example 6; Page 47; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 5;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 43
AAM48510
ID   AAM48510 standard; peptide; 6 AA.
XX
AC   AAM48510;
XX
DT   20-MAR-2002  (first entry)
XX
DE   NBD mutant peptide SEQ ID NO 5.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Example 6; Page 47; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
```

```
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 5;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 DWSWA 6
              |||||
Db          2 DWSWA 6


RESULT 44
AAM48536
ID   AAM48536 standard; peptide; 6 AA.
XX
AC   AAM48536;
XX
DT   20-MAR-2002  (first entry)
XX
DE   Anti-inflammatory peptide SEQ ID NO 39.
XX
KW   Antiinflammatory; antiasthmatic; cytostatic; antipsoriatic; nootropic;
KW   antirheumatic; antiarthritic; osteopathic; antibacterial; virucide;
KW   immunosuppressive; dermatological; neuroprotective; antiatherosclerotic;
KW   antiallergic; membrane translocation domain; NEMO binding domain; eczema;
KW   cytokine; NFkappaB; IkappaB kinase beta; IKKbeta; cancer; psoriasis;
KW   rheumatoid arthritis; osteoarthritis; inflammatory bowel disease;
KW   autoimmune disorder; multiple sclerosis; transplant rejection;
KW   osteoporosis; Alzheimer's disease; atherosclerosis; viral infection;
KW   ataxia telangiectasia; allergy; anaphylaxis; arthritis.
XX
OS   Synthetic.
XX
PN   WO200183554-A2.
XX
PD   08-NOV-2001.
XX
PF   02-MAY-2001; 2001WO-US014346.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (PRAE-) PRAECIS PHARM INC.
PA   (UYYA ) UNIV YALE.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K;
XX
DR   WPI; 2002-121889/16.
XX
PT   Novel antiinflammatory compound comprising membrane translocation domain
PT   fused to NEMO binding sequence, useful for blocking nuclear factor kappaB
PT   activation, and for treating asthma, lung inflammation, psoriasis.
XX
PS   Claim 6; Page 61; 88pp; English.
XX
CC   The invention relates to an antiinflammatory compound (especially
CC   AAM48628-AAM48645), comprising a membrane translocation domain (AAM48620-
CC   AMM48627 or AAM48646-AAM48651) which comprises from 6-15 amino acid
CC   residues, fused to a NEMO binding sequence (AAM48525-AAM48619). The
CC   antiinflammatory compounds have antiasthmatic, cytostatic, antipsoriatic,
CC   antirheumatic, antiarthritic, osteopathic, antibacterial,
CC   immunosuppressive, dermatological, neuroprotective, nootropic,
CC   antiatherosclerotic, virucide and antiallergic activity. The compounds
CC   act as selective inhibitors of cytokine-mediated NFkappaB activation by
CC   blocking interaction of IkappaB kinase beta (IKKbeta) at the NEMO binding
CC   domain that results in inhibition of IKKbeta kinase activation and
CC   subsequent decreased phosphorylation of IkappaB. The compounds are useful
CC   for treating inflammatory disorders, e.g. asthma, lung inflammation or
CC   cancer, psoriasis, rheumatoid arthritis, osteoarthritis, inflammatory
CC   bowel disease, sepsis, vasculitis, bursitis; autoimmune diseases such as
CC   lupus, polymyalgia, scleroderma, granulomatosis, multiple sclerosis;
CC   transplant rejection; osteoporosis; Alzheimer's disease; atherosclerosis;
CC   viral infections; and ataxia telangiectasia. The compounds are also
CC   useful for treating pro-inflammatory responses such as allergies,
CC   urticaria, anaphylaxis, drug or food sensitivity, eczema, dermatitis,
CC   sunburn, aging and arthritis
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 5;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 45
ABU08420
ID   ABU08420 standard; peptide; 6 AA.
XX
AC   ABU08420;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Human NEMO binding site (NBD) mutant peptide #3.
XX
KW   Human; antiinflammatory compound; NEMO binding domain; NBD; IKKbeta;
KW   IkappaB kinase-beta; IkappaB kinase-alpha; IKKalpha; NF-kappaB;
KW   nuclear factor-kappaB induction; inflammatory disorder;
KW   autoimmune disease; osteoporosis; cancer; Alzheimer's disease;
KW   atherosclerosis; viral infection; Ataxia telangiectasia;
KW   transplantation detection; immunosuppressive; osteopathic; cytostatic;
KW   nootropic; neuroprotective; antiatherosclerotic; virucide; vasotropic;
KW   antirheumatic; antiarthritic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2002156000-A1.
XX
PD   24-OCT-2002.
XX
PF   02-MAY-2001; 2001US-00847940.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (MAYM/) MAY M J.
PA   (GHOS/) GHOSH S.
XX
PI   May MJ,  Ghosh S;
XX
DR   WPI; 2003-209142/20.
XX
PT   Novel antiinflammatory peptide compounds comprising NEMO binding domain,
PT   useful for modulating NF-kappaB induction in a cell and for treating NF-
PT   kappaB-mediated inflammation disorders e.g., asthma, psoriasis,
PT   vasculitis.
XX
PS   Claim 22; Page 17; 47pp; English.
XX
CC   The present invention relates to antiinflammatory compounds comprising
CC   NEMO binding domain (NBD) peptides. The NEMO binding domains are found on
CC   IkappaB kinase-beta (IKKbeta) and IkappaB kinase-alpha (IKKalpha)
CC   proteins. The antiinflammatory compounds of the invention are useful for
CC   modulating nuclear factor-kappaB (NF-kappaB) induction in a cell, where
CC   the compounds are capable of blocking the interaction between one or more
CC   IKKs such as IKKalpha or IKKbeta, and NEMO. The antiinflammatory compound
CC   further comprises at least one membrane translocation domain. The
CC   compounds are useful for treating inflammatory disorders, autoimmune
CC   diseases, osteoporosis, cancer, Alzheimer's disease, atherosclerosis,
CC   viral infections, Ataxia telangiectasia, and for transplantation
CC   detection. The compounds of the invention block NF-kappaB induction by
```

```
CC   IKK but do not inhibit the basal activity of NF-kappaB. ABU08418-ABU08432
CC   represent human NBD mutant peptides
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 6;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 46
ABU08421
ID   ABU08421 standard; peptide; 6 AA.
XX
AC   ABU08421;
XX
DT   12-JUN-2003  (first entry)
XX
DE   Human NEMO binding site (NBD) mutant peptide #4.
XX
KW   Human; antiinflammatory compound; NEMO binding domain; NBD; IKKbeta;
KW   IkappaB kinase-beta; IkappaB kinase-alpha; IKKalpha; NF-kappaB;
KW   nuclear factor-kappaB induction; inflammatory disorder;
KW   autoimmune disease; osteoporosis; cancer; Alzheimer's disease;
KW   atherosclerosis; viral infection; Ataxia telangiectasia;
KW   transplantation detection; immunosuppressive; osteopathic; cytostatic;
KW   nootropic; neuroprotective; antiatherosclerotic; virucide; vasotropic;
KW   antirheumatic; antiarthritic; mutant; mutein.
XX
OS   Homo sapiens.
OS   Synthetic.
XX
PN   US2002156000-A1.
XX
PD   24-OCT-2002.
XX
PF   02-MAY-2001; 2001US-00847940.
XX
PR   02-MAY-2000; 2000US-0201261P.
PR   22-AUG-2000; 2000US-00643260.
XX
PA   (MAYM/) MAY M J.
PA   (GHOS/) GHOSH S.
XX
PI   May MJ,  Ghosh S;
XX
DR   WPI; 2003-209142/20.
XX
PT   Novel antiinflammatory peptide compounds comprising NEMO binding domain,
PT   useful for modulating NF-kappaB induction in a cell and for treating NF-
PT   kappaB-mediated inflammation disorders e.g., asthma, psoriasis,
PT   vasculitis.
XX
PS   Claim 22; Page 17; 47pp; English.
XX
CC   The present invention relates to antiinflammatory compounds comprising
CC   NEMO binding domain (NBD) peptides. The NEMO binding domains are found on
CC   IkappaB kinase-beta (IKKbeta) and IkappaB kinase-alpha (IKKalpha)
CC   proteins. The antiinflammatory compounds of the invention are useful for
CC   modulating nuclear factor-kappaB (NF-kappaB) induction in a cell, where
CC   the compounds are capable of blocking the interaction between one or more
CC   IKKs such as IKKalpha or IKKbeta, and NEMO. The antiinflammatory compound
CC   further comprises at least one membrane translocation domain. The
CC   compounds are useful for treating inflammatory disorders, autoimmune
CC   diseases, osteoporosis, cancer, Alzheimer's disease, atherosclerosis,
CC   viral infections, Ataxia telangiectasia, and for transplantation
CC   detection. The compounds of the invention block NF-kappaB induction by
CC   IKK but do not inhibit the basal activity of NF-kappaB. ABU08418-ABU08432
CC   represent human NBD mutant peptides
XX
SQ   Sequence 6 AA;

  Query Match             90.0%;  Score 36;  DB 6;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 DWSWA 6
              |||||
Db          2 DWSWA 6


RESULT 47
ADA61778
ID   ADA61778 standard; peptide; 6 AA.
XX
AC   ADA61778;
XX
DT   20-NOV-2003  (first entry)
XX
DE   IKKbeta NEMO binding domain (NBD) mutant #3.
XX
KW   NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW   antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW   antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW   dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW   gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW   psoriasis; rheumatoid arthritis; osteoarthritis;
KW   inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW   systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW   Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW   necrosis factor kappa B essential modulator; mutant; mutein.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
PN   US2003054999-A1.
XX
PD   20-MAR-2003.
XX
PF   02-MAY-2001; 2001US-00847946.
XX
PR   02-MAY-2000; 2000US-0201261P.
XX
PA   (MAYM/) MAY M J.
PA   (GHOS/) GHOSH S.
PA   (FIND/) FINDEIS M A.
PA   (PHIL/) PHILLIPS K.
PA   (HANN/) HANNIG G.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K,  Hannig G;
XX
DR   WPI; 2003-596541/56.
XX
PT   New compound for diagnosing or treating inflammatory disorders, e.g.
PT   asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT   cancer, comprises a membrane translocation domain and a NEMO binding
PT   sequence.
XX
PS   Example 4; Page 19; 37pp; English.
XX
CC   The invention describes an anti-inflammatory compound comprising (I). The
CC   compound is useful for diagnosing or treating inflammatory disorders,
CC   such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC   inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC   systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC   Alzheimer's disease or viral infection. This is the amino acid sequence
CC   of a I kappa B kinase beta (IKKbeta) NEMO binding domain (NBD) mutant
CC   used in to determine which residues in the NBD are important for binding
CC   NEMO (necrosis factor kappa B essential modulator).
XX
SQ   Sequence 6 AA;
```

```
  Query Match            90.0%;  Score 36;  DB 6;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 48
ADA61812
ID   ADA61812 standard; peptide; 6 AA.
XX
AC   ADA61812;
XX
DT   20-NOV-2003  (first entry)
XX
DE   NFkB essential modulator (NEMO) binding peptide #12.
XX
KW   NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW   antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW   antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW   dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW   gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW   psoriasis; rheumatoid arthritis; osteoarthritis;
KW   inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW   systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW   Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW   necrosis factor kappa B essential modulator.
XX
OS   Unidentified.
XX
PN   US2003054999-A1.
XX
PD   20-MAR-2003.
XX
PF   02-MAY-2001; 2001US-00847946.
XX
PR   02-MAY-2000; 2000US-0201261P.
XX
PA   (MAYM/) MAY M J.
PA   (GHOS/) GHOSH S.
PA   (FIND/) FINDEIS M A.
PA   (PHIL/) PHILLIPS K.
PA   (HANN/) HANNIG G.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K,  Hannig G;
XX
DR   WPI; 2003-596541/56.
XX
PT   New compound for diagnosing or treating inflammatory disorders, e.g.
PT   asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT   cancer, comprises a membrane translocation domain and a NEMO binding
PT   sequence.
XX
PS   Claim 6; Page 23; 37pp; English.
XX
CC   The invention describes an anti-inflammatory compound comprising (I). The
CC   compound is useful for diagnosing or treating inflammatory disorders,
CC   such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC   inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC   systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC   Alzheimer's disease or viral infection. This is the amino acid sequence
CC   of an anti-iflammatory peptide that binds to, and down-regulates,
CC   necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ   Sequence 6 AA;

  Query Match            90.0%;  Score 36;  DB 6;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 49
ADA61811
ID   ADA61811 standard; peptide; 6 AA.
XX
AC   ADA61811;
XX
DT   20-NOV-2003  (first entry)
XX
DE   NFkB essential modulator (NEMO) binding peptide #11.
XX
KW   NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW   antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW   antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW   dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW   gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW   psoriasis; rheumatoid arthritis; osteoarthritis;
KW   inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW   systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW   Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW   necrosis factor kappa B essential modulator.
XX
OS   Unidentified.
XX
PN   US2003054999-A1.
XX
PD   20-MAR-2003.
XX
PF   02-MAY-2001; 2001US-00847946.
XX
PR   02-MAY-2000; 2000US-0201261P.
XX
PA   (MAYM/) MAY M J.
PA   (GHOS/) GHOSH S.
PA   (FIND/) FINDEIS M A.
PA   (PHIL/) PHILLIPS K.
PA   (HANN/) HANNIG G.
XX
PI   May MJ,  Ghosh S,  Findeis MA,  Phillips K,  Hannig G;
XX
DR   WPI; 2003-596541/56.
XX
PT   New compound for diagnosing or treating inflammatory disorders, e.g.
PT   asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT   cancer, comprises a membrane translocation domain and a NEMO binding
PT   sequence.
XX
PS   Claim 6; Page 23; 37pp; English.
XX
CC   The invention describes an anti-inflammatory compound comprising (I). The
CC   compound is useful for diagnosing or treating inflammatory disorders,
CC   such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC   inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC   systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC   Alzheimer's disease or viral infection. This is the amino acid sequence
CC   of an anti-iflammatory peptide that binds to, and down-regulates,
CC   necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ   Sequence 6 AA;

  Query Match            90.0%;  Score 36;  DB 6;  Length 6;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 ADWSW 5
              |||||
Db          1 ADWSW 5


RESULT 50
```

ADA61813
ID ADA61813 standard; peptide; 6 AA.
XX
AC ADA61813;
XX
DT 20-NOV-2003 (first entry)
XX
DE NFkB essential modulator (NEMO) binding peptide #13.
XX
KW NEMO binding domain; NBD; I kappa B kinase beta; IKKbeta;
KW antiinflammatory; antiasthmatic; antipsoriatic; antirheumatic;
KW antiarthritic; osteopathic; antibacterial; immunosuppressive;
KW dermatological; neuroprotective; cytostatic; nootropic; virucide;
KW gene therapy; anti-inflammatory; inflammatory disorder; asthma;
KW psoriasis; rheumatoid arthritis; osteoarthritis;
KW inflammatory bowel disease; sepsis; vasculitis; autoimmune disease;
KW systemic lupus erythematosus; multiple sclerosis; cancer; osteoporosis;
KW Alzheimer's disease; viral infection; NF-kappa B essential modulator;
KW necrosis factor kappa B essential modulator.
XX
OS Unidentified.
XX
PN US2003054999-A1.
XX
PD 20-MAR-2003.
XX
PF 02-MAY-2001; 2001US-00847946.
XX
PR 02-MAY-2000; 2000US-0201261P.
XX
PA (MAYM/) MAY M J.
PA (GHOS/) GHOSH S.
PA (FIND/) FINDEIS M A.
PA (PHIL/) PHILLIPS K.
PA (HANN/) HANNIG G.
XX
PI May MJ, Ghosh S, Findeis MA, Phillips K, Hannig G;
XX
DR WPI; 2003-596541/56.
XX
PT New compound for diagnosing or treating inflammatory disorders, e.g.
PT asthma, psoriasis, rheumatoid arthritis, inflammatory bowel disease or
PT cancer, comprises a membrane translocation domain and a NEMO binding
PT sequence.
XX
PS Claim 6; Page 23; 37pp; English.
XX
CC The invention describes an anti-inflammatory compound comprising (I). The
CC compound is useful for diagnosing or treating inflammatory disorders,
CC such as asthma, psoriasis, rheumatoid arthritis, osteoarthritis,
CC inflammatory bowel disease, sepsis, vasculitis, autoimmune diseases (e.g.
CC systemic lupus erythematosus), multiple sclerosis, cancer, osteoporosis,
CC Alzheimer's disease or viral infection. This is the amino acid sequence
CC of an anti-iflammatory peptide that binds to, and down-regulates,
CC necrosis factor kappa B (NFkB) essential modulator (NEMO).
XX
SQ Sequence 6 AA;

Query Match 90.0%; Score 36; DB 6; Length 6;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 DWSWA 6
|||||
Db 2 DWSWA 6

Search completed: July 23, 2004, 13:18:16
Job time : 53 secs